Nucana Plc (NCNA)
NASDAQ:NCNA
Want to see NCNA full AI Analyst Report?
NCNA Stock Chart & Stats
$3.33
-$0.06(-4.88%)
At close: 4:00 PM EST
$3.33
-$0.06(-4.88%)
Day’s Range― - ―
52-Week Range$1.33 - $39.80
Previous CloseN/A
Volume88.96K
Average Volume (3M)174.33K
Market Cap
$8.78M
Enterprise Value-$14.13M
Total Cash (Recent Filing)$24.21M
Total Debt (Recent Filing)$674.81K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.52
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap-1.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit207.55
Enterprise Value/Ebitda0.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress & Potential Registrational PathClinical signals for NUC-7738 in PD-1 inhibitor‑resistant metastatic melanoma and management’s pursuit of FDA guidance create a structural development pathway. A defined registrational route materially de-risks the program and can enable regulatory-driven value creation and partnership or commercialization options.
Extended Cash Runway Into 2029Having funding visibility into 2029 provides durable operational flexibility to finish Phase 2 enrollment, pursue regulatory meetings, and explore combinations without immediate capital-raising. This reduces short-term dilution risk and gives management time to execute clinical strategy.
Very Low Leverage Reducing Financial RiskMinimal debt limits fixed financial obligations and interest burden, preserving strategic optionality to finance development via equity or partnerships. Low leverage supports resilience through multi-year clinical timelines and reduces bankruptcy risk during extended development phases.
Bears Say
No Revenue And Material Net LossesAs a pre-revenue biotech, NuCana lacks operating cash inflows and remains dependent on external funding. Persistent material losses mean sustained financing needs until commercialization, increasing execution risk and making long-term viability contingent on clinical success or partnerships.
Persistent Cash Burn And FCF VolatilityNegative and volatile free cash flow shows the business cannot self-fund and faces unpredictable funding needs. Even with improved 2025 operating cash flow, reliance on financings raises dilution risk and can divert management attention from R&D to capital markets.
Share Restructuring & Near-term Dilution RiskThe board's request for allotment and pre-emption waivers signals imminent equity issuance and dilution risk to fund operations. Needing shareholder permission for restructuring and fresh authorities underscores structural dependence on equity markets and the potential erosion of existing shareholder value.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $1.33 and its highest was $39.80 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $8.78M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is May 14, 2026 which is in 4 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Mar 19, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.509%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.36% Other Institutional Investors
99.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---